Cobicistat

Shares of Bristol-Myers Squibb Co (NYSE: BMY) were boosted higher on Thursday after the company announced the European Commission approved its Evotaz for the treatment of HIV-1 in adults. Evotaz (atazanayir 300 mg and cobicistat 150 mg) is a daily tablet to be taken with other antiretroviral...

J.P. Morgan (NYSE: JPM) is out with an investor note this morning that reiterates their “Overweight” rating on Gilead Sciences (NASDAQ: GILD) with a price target of $55. The note focused on the company’s Cobicistat drug, which is in the company’s phase 3 pipeline. According to analysts, this drug...